TUESDAY, June 7, 2022
A small study delivers startling results on the power of a new immunotherapy treatment against
All of them had mismatch repair-deficient (MMRd) locally advanced rectal cancer and were given dostarlimab — an anti-PD-1 monoclonal antibody — every three weeks for six…